Innoviva, Inc. (NASDAQ: INVA) is a Burlingame, California-based diversified biopharmaceutical company with a core royalties portfolio and a critical care/infectious disease platform (Innoviva Specialty Therapeutics). In addition to its operating businesses, Innoviva deploys capital as a strategic investor in healthcare assets.

In October 2025, Innoviva invested $17.5 million in the Series B Preferred Stock of Beacon Biosignals, an AI-driven neurotechnology company. This investment reflects Innoviva's strategy of building a portfolio of strategic healthcare investments that complement its core royalty business with high-growth healthcare assets.

Innoviva is not a venture fund and does not have a broad neurotech investment thesis. Its relevance to neurotech is limited to this single disclosed investment. It is best understood as an opportunistic strategic investor rather than a specialist neurotech backer.